|
BCDA | Biocardia, Inc. |
|
|
BCDA | Biocardia, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.01 |
| Leverage | 77.52% |
| Market Cap | $ 61.4m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -7.9m |
| Margin | -7021.49% |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapies for cardiovascular disease. The company is headquartered in San Carlos, California.